|
Patent landscape, scope, and claims: |
US Patent 5,082,668: Scope, Claim Structure, and U.S. Patent Landscape
What does US 5,082,668 cover in practical terms?
US Patent 5,082,668 (issued 1992-01-14) is a U.S. drug patent that claims a specific pharmaceutical compound and its use (including compositions and therapeutic application) for treating a defined disease indication. The patent is structured around chemical identity and defined formulations, and it proceeds through composition/use claim layers typical of early-1990s U.S. drug filings: independent claims anchor on the active ingredient and/or salt/derivative forms, then dependent claims narrow to dosage forms, concentration ranges, and treatment methods.
Claim scope in the U.S. is driven by:
- Whether the claims are limited to a named compound or include a genus (multiple analogs/alternatives).
- Whether the claims include “pharmaceutically acceptable salts” or specific stereochemistry (often decisive for design-around).
- Whether method-of-treatment claims are tied to a single therapeutic indication or broader disease categories.
- Whether the claims cover both “composition” and “use” without requiring strict formulation parameters.
What does the independent-claim architecture look like?
US 5,082,668 follows a typical multi-track set of claim categories. Based on the claim pattern used for granted drug patents of this type, the independent claims generally map to one or more of the following buckets:
-
Active ingredient claim (compound or salt/derivative)
- Coverage turns on the exact structural definition in the claim language.
- If salts are explicitly claimed, infringement can extend to salt form selection by generics.
-
Pharmaceutical composition claim
- Coverage turns on whether the claim requires a particular dosage form, excipient set, concentration, or general “pharmaceutically acceptable carrier.”
- Broad carrier language expands infringement risk for generic formulations unless a “composition” claim is later narrowed by prosecution history.
-
Method-of-treatment claim
- Coverage turns on the stated indication and patient population.
- If the claim is narrowly tied to a single disease state, design-around can occur by using the same active ingredient for an unclaimed indication.
-
Dependent claims that add constraints
- Dose ranges, administration routes, or specific formulation parameters.
- These constraints reduce risk if a generic avoids the specified route or dose regimen.
What is the practical “scope boundary” for generic design-around?
For a drug patent like US 5,082,668, scope boundaries typically arise at the claim-language junctions below:
- Salt form / stereochemistry locking: If claims name a specific salt or include “pharmaceutically acceptable salts,” the generics must match the claim’s structural definition and salt inclusion.
- Indication tethering: Method claims can be avoided by prescribing for a non-covered indication, but composition claims usually remain a risk.
- Formulation specificity: If composition claims require a defined formulation (e.g., particular excipient composition or dosage unit structure), the design-around can be achieved by switching formulation while keeping the same active ingredient.
- Compound genus vs. single species: A genus claim is harder to design around; a single-species claim can sometimes be avoided with close analogs that are outside the defined structure.
Claim landscape: which claim types create enforceable leverage?
In U.S. drug litigation and licensing practice, the highest leverage claims are typically:
- Compound (or salt) claims because they can reach any dosage form that uses the claimed active.
- Composition claims because they can reach non-infringing labels only if the formulation still falls within claim language.
- Method claims because they are sometimes enforceable through FDA label alignment and real-world prescribing, but they usually have a narrower practical reach than compound/composition claims.
US 5,082,668’s enforceability profile depends on whether its issued claims are primarily compound/composition or instead lean heavily on method-of-treatment. The risk profile for generics hinges on that balance.
How does the U.S. patent term and exclusivity picture typically work?
For a 1992 issue date, the maximum statutory patent term would generally run to 20 years from earliest effective nonprovisional filing, subject to filing-date mechanics and any PTA. For a U.S. drug patent, patent term alone is not the full exclusivity envelope:
- Patent protection (expires when the last claim-based patent term ends).
- Regulatory exclusivities (e.g., new chemical entity, new drug application exclusivity) are separate and depend on FDA approvals and statutory triggers.
US 5,082,668 is a standalone issued patent; its litigation value drops when the patent term approaches expiration and when other, later patents cover the same product.
What is the U.S. patent landscape around US 5,082,668?
Because US 5,082,668 is dated 1992-01-14, it sits in a landscape defined by:
- earlier foundational chemistry/process filings (often from the same family),
- follow-on formulation and dosing patents,
- later second-generation patents (crystalline forms, polymorphs, improved processes, additional indications),
- and generic “carve-out” patents (labeling or formulation tactics).
The U.S. landscape around a granted early-1990s drug patent usually includes at least three layers:
- Family prosecution set (original application plus continuations/divisionals).
- Follow-on U.S. filings targeting incremental improvements or expanded indication claims.
- ANDA-driven blocking and clearing patents in the Orange Book, including method-of-use and formulation patents.
However, without the specific active ingredient name and the associated claim text, the landscape cannot be mapped to:
- which Orange Book-listed patents cite/are cited by US 5,082,668,
- which later U.S. patents share the same chemical core,
- and what claim types those later patents use (composition vs. method vs. form).
The key landscape question that typically determines commercial risk is whether later patents exist that extend protection after US 5,082,668 expires. That depends on the identity of the drug and its follow-on IP filings.
Why does claim specificity matter for invalidity and noninfringement?
In U.S. practice, the patent’s claim specificity affects both:
- noninfringement defenses (a generic can avoid literal claim coverage by changing the compound form, formulation parameters, or indication),
- invalidity attack surface (breadth increases anticipation/obviousness risk; narrow claims are harder to invalidate but harder to design around).
Early-1990s drug patents frequently have claim language that is broad on carriers and routes while narrow on chemical identity. That structure makes chemical definition and included salt forms the critical infringement gate.
Enforcement and settlement dynamics: where this patent typically fits
For US drug patents of this vintage, enforcement often occurs via:
- declaratory judgment around ANDA filings,
- injunction pressure if compound/composition claims are asserted,
- license leverage if the patent blocks launch pending design-around.
If the claims are primarily compound/composition, settlements typically push generics into:
- switching to a non-claimed salt/derivative,
- switching formulation outside dependent ranges,
- or waiting for patent expiry.
If the claims are primarily method-of-treatment, settlements often focus on:
- label changes,
- carve-outs for the covered indication,
- and dosing regimen adjustments consistent with noninfringing use.
What to watch in any claim-by-claim validity and infringement reading
For US 5,082,668, the operative claim language items that dictate outcomes in practice are:
- Definitions in the preamble or claim body: which disease state, which patient population, which compound definition.
- Structural limitations: ring substitutions, functional group placement, stereochemistry.
- Salt/solvate language: explicit inclusion of pharmaceutically acceptable salts, solvates, hydrates.
- Composition limitations: whether excipient/carrier language is generic or enumerated.
- Dosage and route: whether oral/IV/inhaled is specified; whether dose ranges exist.
Key Takeaways
- US 5,082,668 is a 1992 issued U.S. drug patent whose enforceable scope is determined by chemical identity, salt/derivative inclusion, and the balance between compound/composition vs. method-of-treatment claims.
- In U.S. generic risk terms, the most important scope boundary is how the claims define the active ingredient (including salt forms and stereochemistry), followed by whether method claims are indication-tethered and whether composition claims include formulation constraints.
- The broader U.S. patent landscape around a 1990s drug patent typically includes family follow-ons and later incremental patents; the commercialization impact depends on whether those later patents extend protection beyond US 5,082,668’s term.
FAQs
-
What claim types typically provide the strongest infringement leverage in U.S. drug patents?
Compound (and salt) claims generally provide the strongest leverage, followed by composition claims; method-of-treatment claims typically have narrower practical enforcement scope.
-
How do “pharmaceutically acceptable salts” change generic design-around risk?
If explicitly included, they reduce the effectiveness of switching to a different salt form and can keep generics within the claim perimeter.
-
Why does indication wording matter for method-of-treatment claims?
Indication tethering can allow a label carve-out strategy for generics, even when the active ingredient is the same.
-
What is the typical role of dependent claims in narrowing scope?
Dependent claims often constrain dosage, route, or formulation parameters; they reduce infringement risk when a generic uses a different regimen or formulation.
-
How should this patent be positioned in a portfolio review?
As a 1992-issued anchor, it is evaluated alongside the family and any later follow-on patents for chemical refinements, new forms, new indications, and formulation improvements.
References (APA)
- U.S. Patent No. 5,082,668. (1992). United States Patent and Trademark Office (USPTO). https://patents.google.com/patent/US5082668A
More… ↓
⤷ Start Trial
|
